TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17456380
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg daily for two months
Study: 7618457
Drug: Gonadotropin releasing
Normalized name: Gonadotropin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin releasing hormone agonist treatment (D‐Trp‐6‐LHRH depot) before hysterectomy
Study: 26899745
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone 500 mg every 12 hours for 3 days
Study: 26899745
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone 500 mg every 12 hours for 7 days
Study: 16238908
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (EPO) 40,000 U once weekly
Study: 12090862
Drug: 0.625 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/d of conjugated estrogens and 2.5 mg of medroxyprogesterone acetate (n = 1380)
Study: 22313792
Drug: Desmopressin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin plus oxybutynin (5 mg)
Study: 17767476
Drug: Rofecoxib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (25 mg/day) + Proton Pump Inhibitor (PPI)
Study: 17767476
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitor (PPI) alone
Study: 12680744
Drug: Procyclidine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procyclidine (15 mg, oral)
Study: 10100062
Drug: Post-glucose load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-glucose load plasma insulin in hypertensive patients with microalbuminuria (n = 14)
Study: 1802019
Drug: Mitoxantrone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 1.25 mg/m2/day
Study: 31429205
Drug: TAK-385 (320/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-385 (320/80 mg loading/maintenance)
Study: 31429205
Drug: TAK-385 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-385 (various doses)
Study: 15612857
Drug: Alternative individual
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative individual treatment based on routine drug and alcohol therapy topics
Study: 9394699
Drug: 90 g
Normalized name: Fora G90 Glucose Test Strip
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 g cooked field bean flour/d (groups B and C)
Study: 9394699
Drug: 90 g
Normalized name: Fora G90 Glucose Test Strip
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 g raw field bean flour/d (group D)
Study: 9394699
Drug: 90 g
Normalized name: Fora G90 Glucose Test Strip
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 g control flour/d (group A)
Study: 7696825
Drug: Pamidronate (time-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (time-release preparation)
Study: 7696825
Drug: Pamidronate (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (standard tablet preparation)
Study: 7696825
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of pamidronate and use of antacid medication
Study: 2954077
Drug: CAF (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF (cyclophosphamide 600 mg/m2 + 5-fluorouracil 750 mg/m2 + adriamycin 45 mg/m2)
Study: 28393781
Drug: Levosimendan at
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan at 0.1 μg/kg/min
Study: 28393781
Drug: Dobutamine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine at 5 μg/kg/min
Study: 26237195
Drug: Conventional circular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional circular chainring (CC)
Study: 10889125
Drug: Aggressive lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive lowering of LDL cholesterol levels to <100 mg/dL
Study: 10889125
Drug: Low-dose anticoagulation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose anticoagulation
Study: 10889125
Drug: Moderate reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate reduction of LDL cholesterol to 132-136 mg/dL
Study: 1568366
Drug: d-fenfluramine (d-F)
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-fenfluramine (d-F) 15 mg, two capsules daily
Study: 27397441
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 mcg/kg loading dose over 15 min, followed by 0.5 mcg/kg/h maintenance infusion)
Study: 17073850
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with a plasmatic target concentration of 4 mg/l (group P; n= 26)
Study: 16338276
Drug: Saquinavir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir (600 mg) with water (control)
Study: 16338276
Drug: Saquinavir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir (600 mg) with Seville orange juice
Study: 7720343
Drug: Random urine
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random urine sample with threshold albumin-creatinine ratio of > or = 3.0 mg/mmol
Study: 7720343
Drug: Overnight urine
Normalized name: URINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight urine collection with threshold values of 2.5 mg/mmol for men and 4.5 mg/mmol for women
Study: 2119417
Drug: Pravastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10 mg b.i.d. for 6 weeks, then 20 mg b.i.d. for 6 weeks)
Study: 29373395
Drug: Real rDTMS
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real rDTMS treatment
Study: 29373395
Drug: Sham rDTMS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham rDTMS treatment
Study: 28318388
Drug: Nutritional intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional intervention with individualized nutrition plan (1.0‐1.5 g/kg) and dietary advice
Study: 18249333
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standardized institutional practice without warmed intravenous fluids)
Study: 1625092
Drug: Human growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human growth hormone (hGH) alone
Study: 2681348
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with hGH and oxandrolone
Study: 27655325
Drug: 4 mL/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL/Kg of crystalloid
Study: 26588599
Drug: Flapless surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flapless surgical protocol (n = 20 patients; 32 implants)
Study: 26588599
Drug: Flapped surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flapped surgical protocol (n = 21 patients; 40 implants)
Study: 24982464
Drug: VAC (vincristine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC (vincristine, dactinomycin, and cyclophosphamide) with 1.5 g/m² of cyclophosphamide
Study: 24982464
Drug: VAI (vincristine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAI (vincristine, dactinomycin, and ifosfamide) with 6 g/m² of ifosfamide
Study: 19244263
Drug: Levobupivacaine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine infusion for femoral nerve
Study: 19244263
Drug: Levobupivacaine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine infusion for sciatic nerve
Study: 9788829
Drug: Echocardiography-guided ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Echocardiography-guided ethanol septal reduction (2 to 5 mL of absolute ethanol injected into the septal artery)
Study: 15130899
Drug: Intramuscular gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular gold
Study: 892953
Drug: Drug +
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug + alcohol placebo
Study: 24021094
Drug: Progressive Goal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive Goal Attainment Program (PGAP) - 10 weekly individual sessions of structured active rehabilitation in addition to usual care.
Study: 22409094
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (receiving cognitive behavioral therapy and pharmacotherapy)
Study: 19603054
Drug: 5‐methyltetrahydrofolate (5‐MTHF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐methyltetrahydrofolate (5‐MTHF) 15 mg/day for 3 weeks
Study: 9740919
Drug: Comprehensive management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive management approach including preoperative evaluation, meticulous exenterative surgery, supervised immunotherapy, medical management with corticosteroids, patient self-cleansing, and close clinical follow-up.
Study: 27127315
Drug: Alfuzosin SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin SR 10 mg
Study: 23203138
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride XR 60 mg once daily for 10 days in healthy volunteers
Study: 23203138
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 60 mg XR once daily for either 2 weeks or 12 weeks in patients with overactive bladder
Study: 23203138
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride XR 60 mg
Study: 17710365
Drug: GLU +
Normalized name: Glu
DrugBank: gamma-Glutamylcysteine (DB03408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLU + FG (1.8 g x kg BW(‐1) + 1.99 +/‐ 0.20 mg x kg(‐1) 4‐hydroxyisoleucine)
Study: 1745512
Drug: Pilocarpine (2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine (2% liquid ophthalmic drop preparation, four drops three times per day for 6 weeks)
Study: 1745512
Drug: Placebo (identically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identically appearing solution, same dosing schedule and duration)
Study: 6751182
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (nafcillin for 6 weeks plus gentamicin for 2 weeks) in parenteral drug addicts
Study: 6751182
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (nafcillin for 6 weeks plus gentamicin for 2 weeks) in nonaddicts
Study: 6751182
Drug: Single therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single therapy (nafcillin for 6 weeks) in both groups
Study: 23545428
Drug: Fixed low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed low-dose morphine/oxycodone (3 mg/2 mg)
Study: 23545428
Drug: Flexible dose
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible dose morphine/oxycodone
Study: 19137769
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus ointment
Study: 12824978
Drug: Intravenous ritodrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ritodrine (111 microg/min for 20 minutes)
Study: 9832096
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (0.4 mg)
Study: 12824978
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium chloride 0.9% (placebo)
Study: 10638892
Drug: Bupivacaine 4
Normalized name: BUPIVACAINE 400MG/MELOXICAM 12MG/VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 4 mg plus fentanyl 20 microg (Group A)
Study: 10638892
Drug: Bupivacaine 10
Normalized name: BUPivacaine 100 mg parenteral implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 10 mg (Group B)
Study: 3090492
Drug: Levonorgestrel‐releasing Norplant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel‐releasing Norplant implants
Study: 20685721
Drug: Pulsed radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed radiofrequency treatment
Study: 21679043
Drug: IV diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV diclofenac 37.5 mg
Study: 8665883
Drug: ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac 30 mg
Study: 21056807
Drug: oral acetylsalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral acetylsalicylic acid (ASA) 325 mg
Study: 21056807
Drug: oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral diclofenac 50 mg
Study: 17693428
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment (appliance removal)
Study: 12410188
Drug: Daily home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily home PCA monitoring
Study: 6826111
Drug: 30 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 micrograms ethinyloestradiol plus 2.5 mg norethisterone
Study: 17555114
Drug: Human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human recombinant erythropoietic agents (specific dosage schemes not provided)
Study: 17555114
Drug: Darbopoietin alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darbopoietin alpha (specific dosage schemes not provided)
Study: 11966551
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (NO-generating gel)
Study: 6342359
Drug: Extensive radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extensive radiation therapy (RT) followed by chemotherapy (CT)
Study: 31797710
Drug: Carnitine infusion
Normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carnitine infusion over 10 min 2 hours prior to radiocontrast administration and 24 hours post CT
Study: 31797710
Drug: Tadalafil administration
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil administration 2 hours prior to radiocontrast administration and the subsequent day
Study: 17976261
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) preparation of racemic ibuprofen
Study: 16390770
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day 17beta-estradiol combined with 5 or 10 mg/day dydrogesterone
Study: 16390770
Drug: 2 mg/day
Normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/day 17beta-estradiol combined with 10 or 20 mg/day dydrogesterone
Study: 12581544
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg/d to 400 mg/d)
Study: 7533824
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine (100 mg/m2/week or 80 mg/m2/week for prior radiation therapy patients)
Study: 7740337
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine
Study: 824875
Drug: Short term
Normalized name: Short Term Oral Swab System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short term treatment with Partusisten only
Study: 31527700
Drug: Hypnosis plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis plus treatment-as-usual (EG, n=8)
Study: 31527700
Drug: Treatment-as-usual only
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual only (CG, n=10)
Study: 17096032
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (exact dosage and duration not specified)
Study: 9285885
Drug: Zinc absorption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc absorption from a standard breakfast labelled with 3 mg 67Zn.
Study: 9285885
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 0.5 mg 70Zn (as citrate).
Study: 9285885
Drug: Urinary zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary zinc excretion measurement.
Study: 8362773
Drug: Fosinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (10 to 40 mg)
Study: 8362773
Drug: Isradipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (5 to 20 mg)
Study: 9568783
Drug: Calcium supplements
Normalized name: CALCIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplements
Study: 24114665
Drug: Specific anti-osteoporotic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific anti-osteoporotic drugs
Study: 24114665
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D use among specific osteoporosis drug users
Study: 20934601
Drug: Passion fruit
Normalized name: passion fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passion fruit peel extract (PFP), 150 mg daily for 2 months
Study: 12803510
Drug: lisinopril 10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril 10 mg/day
Study: 12803510
Drug: lisinopril 10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril 10 mg/day and pentoxifylline 600 mg/day for nine months
Study: 7056105
Drug: Oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral verapamil therapy in chronic AF with rapid rate at rest
Study: 7056105
Drug: Oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral verapamil therapy in chronic AF with accelerated rate during exercise
Study: 7056105
Drug: Oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral verapamil therapy in paroxysmal AF
Study: 25142999
Drug: Lopinavir-ritonavir (LPV-r)
Normalized name: lopinavir / ritonavir
DrugBank: Lopinavir (DB01601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lopinavir-ritonavir (LPV-r) 400-100 mg twice/day for 29.5 days followed by P. ginseng 500 mg twice/day for 2 weeks
Study: 25142999
Drug: P. ginseng
Approvals — FDA: no, EMA: no, PMDA: no
Description: P. ginseng 500 mg twice/day for 2 weeks
Study: 21070230
Drug: telcagepant 280/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: telcagepant 280/300 mg
Study: 18614724
Drug: Sugared cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugared cocoa (22 g cocoa powder)
Study: 2190933
Drug: Cefuroxime (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (one dose)
Study: 489772
Drug: Once-daily sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily sotalol administration (80 to 320 mg)
Study: 489772
Drug: Twice-daily sotalol
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily sotalol administration (80 to 320 mg)
Study: 23856779
Drug: Deleobuvir 800
Normalized name: Deleobuvir
DrugBank: Deleobuvir (DB14850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deleobuvir 800 mg q8h for 5 days
Study: 23856779
Drug: Deleobuvir 1200
Normalized name: Deleobuvir
DrugBank: Deleobuvir (DB14850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deleobuvir 1200 mg q8h for 5 days
Study: 21881539
Drug: 10-mg ramipril
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg ramipril
Study: 17372095
Drug: Duct tape
Normalized name: Sus scrofa bile duct preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duct tape occlusion therapy (moleskin with transparent duct tape)
Study: 14980943
Drug: Prophylactic infusion
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic infusion of IV phenylephrine at 100 microg/min for 3 min, then 100 microg/min as needed
Study: 8175974
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose human synthetic BNP infusion (4 pmol/kg.min for 1 h)
Study: 3066519
Drug: Rifaximin (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (three 200 mg tablets/die for 7 days)
Study: 27544607
Drug: Drug-eluting stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stent (DES) implantation
Study: 12492745
Drug: Pantoprazole 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 10 mg
Study: 10632407
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no FSH treatment)
Study: 9010698
Drug: Entacapone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone (200 mg) and Imipramine (75 mg) in combination
Study: 28490581
Drug: Four-valent HPV
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-valent HPV vaccine
Study: 22713768
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) initiated in 97 children
Study: 25448437
Drug: Gp 2
Normalized name: Pulmari GP 20mg-100mg/5ml Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gp 2 - oral health education talk and parental toothbrushing training, reinforced every 6 months
Study: 20380654
Drug: Initial subcutaneous
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial subcutaneous bolus of 1.4 U
Study: 20380654
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion without initial bolus
Study: 17666472
Drug: Cinacalcet hydrochloride
Normalized name: Cinacalcet Hydrochloride
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cinacalcet hydrochloride (30 mg twice daily to 90 mg four times daily) for 16 weeks
Study: 8369579
Drug: Cyclosporin 5
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin 5 mg/kg/day
Study: 8369579
Drug: Etretinate 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etretinate 0.75 reduced to 0.5 mg/kg/day